DDInter6 DDInter899
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Abciximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloprost
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Collagenase clostridium histolyticum
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Tinzaparin
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Reteplase
Abciximab may cause a minor interaction that can limit clinical effects when taken with Capsicum
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum
Abciximab may lead to a major life threatening interaction when taken with Tinzaparin
Abciximab may lead to a major life threatening interaction when taken with Reteplase